JPRN-UMIN000035638招募中2 期
A phase II study of TFTD plus Bevacizumab in patients with unresectable advanced colorectal cancer - TFTD plus Bmab for unresectable colorectal cancer
Department of Gastroenterological, Breast and Endocrine Surgery,Yamaguchi University Graduate School of Medicine0 个研究点目标入组 45 人开始时间: 2019年1月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who conflict with one of the following will not be included in this clinical study. 1. Patients with simultaneous active malignant disease. 2. Patients who had history of deep vein thrombosis, pulmonary embolism, or other significant thromboembolic disorder (thrombosis of the venous port or catheter or superficial venous thrombosis is not considered serious). 3. Patients with serious bleeding disorder, vasculitis, or serious gastrointestinal bleeding within 3 months before acquiring consent. 4. Patients with gastrointestinal perforation and / or history of fistula. 5. Patients with a history of pulmonary hemorrhage (hemoptysis). 6. Despite standard medical management, patients with uncontrollable arterial hypertension. 7. Patients with serious or unrecovered wounds, a history of peptic ulcer or fracture. 8. Patients with bowel obstruction, complication of inflammatory bowel disease or extensive intestinal resection, patients with Crohn's disease, ulcerative colon or chronic diarrhea. 9. Patients with serious drug allergy. 10. Patients with infection with fever over 38.0. 11. Patients with double active cancers which mean synchronous double cancers or metachronous double cancers with a disease-free period within 5 years. 12. Patients with brain metastasis. 13. Patients with severe complications such as the following. Patients with complications of infection during antibiotic administration. Patients with complications of treatment or poor control due to continued use of insulin. Patients of complication of hypertension with poor control. Patients with myocardial infarction that developed within 6 months. Patients with unstable angina. Patients in which liver cirrhosis was complicated. Patients in which interstitial pneumonia and pulmonary fibrosis are complicated. 14. Pregnant or nursing female. 15. Patient with mental illness. 16. Not appropriate for the study at the physician's assessment.
研究者
相似试验
招募中
2 期
TAS-CC5 Studycolorectal cancerJPRN-jRCT1031220613Takeshi Yamada105
尚未招募
不适用
A phase 1B/2 study of trastuzumab, bevacizumab with paclitaxel for HER2-positive gastric cancer in a second-line therapyNeoplasmsKCT0008209Kangbuk Samsung Medical Center47
招募中
2 期
Multicenter phase II study of adding bevacizumab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapiesColorectal cancerJPRN-UMIN000006476Cubu Clinical Oncology Group (CCOG)30
已完成
2 期
A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapyColorectal CancerJPRN-UMIN000022705Osaka medical Center for Cancer and Cardiovascular Diseases20
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE